Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2018, Vol. 23 ›› Issue (1): 99-103.doi: 10.12092/j.issn.1009-2501.2018.01.019

Previous Articles     Next Articles

Clinical trial of methylprednisolone and batroxobin combined with hyperbaric oxygen in the treatment of sudden deafness

WANG Jingbo, FANG Lian, SONG Xiaoxiao, ZHOU Qinshuang   

  1. Department of Otolaryngology,the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang, China
  • Received:2017-05-17 Revised:2017-05-26 Online:2018-01-26 Published:2018-02-07

Abstract:

AIM: To observe the clinical efficacy and safety of methylprednisolone and batroxobin combined with hyperbaric oxygen in the treatment of sudden deafness, and to explore their effect on blood coagulation function and blood vessel function.  METHODS: Ninety-two patients with sudden deafness were randomly divided into the control group and the treatment group, forty-six cases for each group. The control group were given batroxobin injection initial dose 10 BU, maintenance dose 5 BU, two days one time, intravenous plus hyperbaric oxygen therapy; and the treatment group were given methylprednisolone sodium succinate injection 40 mg, qd, intravenous plus batroxobin injection plus hyperbaric oxygen therapy. After treatment for 10 d, the clinical efficacy and occurrence of adverse drug reactions were observed. The levels of plasma prothrombin time (PT), activated partial thromboplastin time (APTT), soluble vascular cell adhesion molecule-1 (sVCAM-1), intercellular adhesion molecule-1 (ICAM-1), vascular endothelial growth factor (VEGF), superoxide dismutase (SOD), thromboxane B2 (TXB2) and vascular endothelial cadherin (VE-cadherin) were compared. RESULTS:The total effective rate in the treatment group and the control group were 97.83%(45/46) and 80.43% (37/46), respectively (P<0.05). PT of the treatment group and control group were (20.34±3.21) and (15.18±2.13) s; APTT were (51.47±4.34) and (40.01±3.56) s; sVCAM-1 were (113.35±20.76) and (172.14±21.37) μg/L; ICAM-1 were (67.12±14.35) and (95.16±14.52)μg/L; VEGF were (92.75±15.36) and (75.12±14.18) μg/L; SOD were (133.47±11.69) and (112.37±10.43) ng/L; TXB2 were (198.74±16.31) and (237.15±17.17) ng/L; VE-cadherin were (3.02±0.57) and (4.41±0.59) mg/L , respectively, the differences were all statistically significant (P<0.05). The adverse drug reactions were mainly headache, gastrointestinal discomfort, flustered, itchy skin; the incidence of adverse drug reactions in treatment group and control group were 17.39% and 15.22%, respectively (P>0.05). CONCLUSION: Methylprednisolone and batroxobin combined with hyperbaric oxygen have significantly curative effect in the treatment of sudden deafness, which improve the patient's blood coagulation function, endothelial function, repair endothelial injury, and present no increasing the adverse drug reactions.

Key words: methylprednisolone, batroxobin, hyperbaric oxygen, blood coagulation function, blood vessel function

CLC Number: